6 research outputs found
The impact of COVID-19 on surgical activity
AimÂ
This study aims to examine the impact of COVID-19 on surgical activity in a Model 3 Hospital.Â
MethodsÂ
A retrospective, observational study assessing data collected over a 3-month period (February to April) in 2019 and 2020.Â
ResultsÂ
There was an overall reduction in surgical activity between 2019 and 2020. This impact was felt most acutely in the month of April where elective theatre and endoscopy procedures fell from 131 to 9 (93%) and 399 to 102 (74%) respectively. The number of emergency department admissions reduced from 534 to 408 (24%) and the number requiring surgical intervention fell from 166 to 122 (27%). Attendance at surgical outpatients fell from 1,211 to 677 (44%) between the 2019 and 2020. In April, attendance reduced from 456 to 52 (86%).Â
DiscussionÂ
This study has quantified the reduction in surgical department activity in our Model 3 Hospital. This reduction in scheduled and non-scheduled care could be extrapolated nationally to inform service planning, which will become increasingly challenged unless action to address the service deficit is taken soon.</p
Clinical trials in cancer screening, prevention and early diagnosis (SPED): a systematic mapping review
Background: Global annual cancer incidence is forecast to rise to 27.5Â M by 2040, a 62% increase from 2018. For most cancers, prevention and early detection are the most effective ways of reducing mortality. This study maps trials in cancer screening, prevention, and early diagnosis (SPED) to identify areas of unmet need and highlight research priorities. Methods: A systematic mapping review was conducted to evaluate all clinical trials focused on cancer SPED, irrespective of tumour type. The National Cancer Research Institute (NCRI) portfolio, EMBASE, PubMed and Medline were searched for relevant papers published between 01/01/2007 and 01/04/2020. References were exported into Covidence software and double-screened. Data were extracted and mapped according to tumour site, geographical location, and intervention type. Results: One hundred seventeen thousand seven hundred one abstracts were screened, 5157 full texts reviewed, and 2888 studies included. 1184 (52%) trials focussed on screening, 554 (24%) prevention, 442 (20%) early diagnosis, and 85 (4%) a combination. Colorectal, breast, and cervical cancer comprised 61% of all studies compared with 6.4% in lung and 1.8% in liver cancer. The latter two are responsible for 26.3% of global cancer deaths compared with 19.3% for the former three. Number of studies varied markedly according to geographical location; 88% were based in North America, Europe, or Asia. Conclusions: This study shows clear disparities in the volume of research conducted across different tumour types and according to geographical location. These findings will help drive future research effort so that resources can be directed towards major challenges in cancer SPED
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response with Infection Severity in Patients with Cancer: A National COVID Cancer Cross-sectional Evaluation
Importance: Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer. Objective: To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer. Design, Setting, and Participants: This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. Adults with a known or reported cancer diagnosis who had completed their primary SARS-CoV-2 vaccination schedule were included. This analysis ran from September 1, 2021, to March 4, 2022, a period covering the expansion of the UK's third-dose vaccination booster program. Interventions: Anti-SARS-CoV-2 COV-S antibody test (Elecsys; Roche). Main Outcomes and Measures: Odds of SARS-CoV-2 breakthrough infection and COVID-19 hospitalization. Results: The evaluation comprised 4249 antibody test results from 3555 patients with cancer and 294230 test results from 225272 individuals in the noncancer population. The overall cohort of 228827 individuals (patients with cancer and the noncancer population) comprised 298479 antibody tests. The median age of the cohort was in the age band of 40 and 49 years and included 182741 test results (61.22%) from women and 115737 (38.78%) from men. There were 279721 tests (93.72%) taken by individuals identifying as White or White British. Patients with cancer were more likely to have undetectable anti-S antibody responses than the general population (199 of 4249 test results [4.68%] vs 376 of 294230 [0.13%]; P <.001). Patients with leukemia or lymphoma had the lowest antibody titers. In the cancer cohort, following multivariable correction, patients who had an undetectable antibody response were at much greater risk for SARS-CoV-2 breakthrough infection (odds ratio [OR], 3.05; 95% CI, 1.96-4.72; P <.001) and SARS-CoV-2-related hospitalization (OR, 6.48; 95% CI, 3.31-12.67; P <.001) than individuals who had a positive antibody response. Conclusions and Relevance: The findings of this cross-sectional study suggest that COV-S antibody testing allows the identification of patients with cancer who have the lowest level of antibody-derived protection from COVID-19. This study supports larger evaluations of SARS-CoV-2 antibody testing. Prevention of SARS-CoV-2 transmission to patients with cancer should be prioritized to minimize impact on cancer treatments and maximize quality of life for individuals with cancer during the ongoing pandemic.
Recommended from our members
COVIDiSTRESS diverse dataset on psychological and behavioural outcomes one year into the COVID-19 pandemic
During the onset of the COVID-19 pandemic, the COVIDiSTRESS Consortium launched an open-access global survey to understand and improve individuals’ experiences related to the crisis. A year later, we extended this line of research by launching a new survey to address the dynamic landscape of the pandemic. This survey was released with the goal of addressing diversity, equity, and inclusion by working with over 150 researchers across the globe who collected data in 48 languages and dialects across 137 countries. The resulting cleaned dataset described here includes 15,740 of over 20,000 responses. The dataset allows cross-cultural study of psychological wellbeing and behaviours a year into the pandemic. It includes measures of stress, resilience, vaccine attitudes, trust in government and scientists, compliance, and information acquisition and misperceptions regarding COVID-19. Open-access raw and cleaned datasets with computed scores are available. Just as our initial COVIDiSTRESS dataset has facilitated government policy decisions regarding health crises, this dataset can be used by researchers and policy makers to inform research, decisions, and policy
Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19
COVID-19 pathogenesis is associated with an exaggerated immune response. However, the specific cellular mediators and inflammatory components driving diverse clinical disease outcomes remain poorly understood. We undertook longitudinal immune profiling on both whole blood and peripheral blood mononuclear cells of hospitalized patients during the peak of the COVID-19 pandemic in the United Kingdom. Here, we report key immune signatures present shortly after hospital admission that were associated with the severity of COVID-19. Immune signatures were related to shifts in neutrophil to T cell ratio, elevated serum IL-6, MCP-1, and IP-10 and modulation of CD14+ monocyte phenotype and function. Modified features of CD14+ monocytes included poor induction of the prostaglandin-producing enzyme, COX-2, and enhanced expression of the cell cycle marker Ki-67. Longitudinal analysis revealed reversion of some immune features back to the healthy median level in patients with a good eventual outcome. These findings identify previously unappreciated alterations in the innate immune compartment of patients with COVID-19 and lend support to the idea that therapeutic strategies targeting release of myeloid cells from bone marrow should be considered in this disease. Moreover, they demonstrate that features of an exaggerated immune response are present early after hospital admission, suggesting that immunomodulating therapies would be most beneficial at early time points
Recommended from our members
Author Correction: COVIDiSTRESS diverse dataset on psychological and behavioural outcomes one year into the COVID-19 pandemic (Scientific Data, (2022), 9, 1, (331), 10.1038/s41597-022-01383-6)
The original version of this Article contained an error in the spelling of the author Krzysztof Hanusz, which was incorrectly given as Hanusz Krzysztof. This has now been corrected in both the PDF and HTML versions of the Article